Treatment experience with nonseminomatous testicular cancer in patients with stage II and stage III disease

H. Grant Taylor, Archie W. Brown, William M. Butler, Martin D. Weltz, Jeffrey L. Berenberg, David G. McCleod, Jackson E. Fowler, Ray E. Stutzman, Johannes Blom

Research output: Contribution to journalArticle

Abstract

Thirty‐eight patients with nonseminomatous testicular cancer were treated with cis‐platinum, bleomycin, and vinblastine in combination without a prolonged maintenance phase. Twenty‐six patients with Stage III disease were treated. Seventy‐six percent of those patients treated achieved, complete remission. At a median survival time of 30 months, no patient who achieved a complete remission has relapsed. Twelve Stage II patients given adjuvant therapy remain free of disease at a median time of 23 months. Markedly elevated serum lactate dehydrogenase levels and massive disease were common findings in the patients who did not achieve complete remission. One drug death occurred secondary to sepsis. Symptoms of depression and anxiety were significant dose‐limiting factors in this group of patients.

Original languageEnglish (US)
Pages (from-to)1110-1115
Number of pages6
JournalCancer
Volume48
Issue number5
DOIs
StatePublished - Sep 1 1981

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment experience with nonseminomatous testicular cancer in patients with stage II and stage III disease'. Together they form a unique fingerprint.

  • Cite this

    Taylor, H. G., Brown, A. W., Butler, W. M., Weltz, M. D., Berenberg, J. L., McCleod, D. G., Fowler, J. E., Stutzman, R. E., & Blom, J. (1981). Treatment experience with nonseminomatous testicular cancer in patients with stage II and stage III disease. Cancer, 48(5), 1110-1115. https://doi.org/10.1002/1097-0142(19810901)48:5<1110::AID-CNCR2820480511>3.0.CO;2-3